Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma

Lead author Kevin Hakimi discusses the background and results of the study, “Interim analysis of PADRES (prior axitinib as a determinant of outcome of renal surgery NCT03438708) clinical trial,” which he presented at the 2022 AUA Annual Meeting (LBA01-08).